These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20354132)

  • 1. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; List AF; Cuthbertson D; Paquette R; Ganetzky R; Latham D; Paulic K; Afable M; Saba HI; Loughran TP; Maciejewski JP
    J Clin Oncol; 2010 May; 28(13):2253-8. PubMed ID: 20354132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; Tiu RV; Komrokji R; Lancet J; Advani AS; Afable M; Englehaupt R; Juersivich J; Cuthbertson D; Paleveda J; Tabarroki A; Visconte V; Makishima H; Jerez A; Paquette R; List AF; Maciejewski JP
    Blood; 2012 Dec; 120(25):4945-51. PubMed ID: 22915641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
    Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
    Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of higher-risk myelodysplastic syndrome.
    Garcia-Manero G
    Semin Oncol; 2011 Oct; 38(5):673-81. PubMed ID: 21943674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
    Sekeres MA; Othus M; List AF; Odenike O; Stone RM; Gore SD; Litzow MR; Buckstein R; Fang M; Roulston D; Bloomfield CD; Moseley A; Nazha A; Zhang Y; Velasco MR; Gaur R; Atallah E; Attar EC; Cook EK; Cull AH; Rauh MJ; Appelbaum FR; Erba HP
    J Clin Oncol; 2017 Aug; 35(24):2745-2753. PubMed ID: 28486043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
    Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
    Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
    Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
    Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; O'Keefe C; List AF; Paulic K; Afable M; Englehaupt R; Maciejewski JP
    Am J Hematol; 2011 Jan; 86(1):102-3. PubMed ID: 21080340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
    Ball B; Zeidan A; Gore SD; Prebet T
    Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
    Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
    Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eprenetapopt (APR-246) and Azacitidine in
    Sallman DA; DeZern AE; Garcia-Manero G; Steensma DP; Roboz GJ; Sekeres MA; Cluzeau T; Sweet KL; McLemore A; McGraw KL; Puskas J; Zhang L; Yao J; Mo Q; Nardelli L; Al Ali NH; Padron E; Korbel G; Attar EC; Kantarjian HM; Lancet JE; Fenaux P; List AF; Komrokji RS
    J Clin Oncol; 2021 May; 39(14):1584-1594. PubMed ID: 33449813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
    Mongiorgi S; De Stefano A; Ratti S; Indio V; Astolfi A; Casalin I; Pellagatti A; Paolini S; Parisi S; Cavo M; Pession A; McCubrey JA; Suh PG; Manzoli L; Boultwood J; Finelli C; Cocco L; Follo MY
    Clin Epigenetics; 2023 Feb; 15(1):27. PubMed ID: 36803590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
    Pollyea DA; Zehnder J; Coutre S; Gotlib JR; Gallegos L; Abdel-Wahab O; Greenberg P; Zhang B; Liedtke M; Berube C; Levine R; Mitchell BS; Medeiros BC
    Haematologica; 2013 Apr; 98(4):591-6. PubMed ID: 23242596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
    Raza A; Reeves JA; Feldman EJ; Dewald GW; Bennett JM; Deeg HJ; Dreisbach L; Schiffer CA; Stone RM; Greenberg PL; Curtin PT; Klimek VM; Shammo JM; Thomas D; Knight RD; Schmidt M; Wride K; Zeldis JB; List AF
    Blood; 2008 Jan; 111(1):86-93. PubMed ID: 17893227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.
    Cherian MA; Tibes R; Gao F; Fletcher T; Fiala M; Uy GL; Westervelt P; Jacoby MA; Cashen AF; Stockerl-Goldstein K; DiPersio JF; Vij R
    Leuk Lymphoma; 2016 Nov; 57(11):2535-40. PubMed ID: 27122296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
    Sekeres MA
    Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.